LMTX®, TauRx's second-generation tau aggregation inhibitor (TAI), is currently under investigation as a potential disease-modifying treatment for Alzheimer’s disease. Existing symptomatic treatments for Alzheimer’s only transiently address the symptoms and do not slow disease progression. LMTX® acts by reducing levels of aggregated or misfolded tau proteins, which are associated with the progressive neurodegeneration which is the hallmark of Alzheimer’s disease.

LMTX® shares the same active ingredient (methylthioninium [MT]) and mode of action as rember®, TauRx’s first generation TAI, Phase 2 clinical trials of which provided the first clinical demonstration that a new therapy targeting protein aggregation could reduce the rate of progression of this deadly disease.

TauRx has now completed two large Phase 3 clinical trials of LMTX® in Alzheimer’s disease and has started a new clinical trial, named LUCIDITY; please follow this link for a summary of the Phase 3 programme and trial results.

Development history